Breast Cancer
Conditions
Interventions
Case group:None
Sponsors
Chinese Academy of Medical Sciences / Peking Union Medical College,school of nursing
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The diagnosis was confirmed by pathological examination and clinical imaging examination; 2. Accept anthracycline chemotherapy scheme; FAC: (F: Fluorouracil, fluorouracil; A: Pirarubicin, THP, pirarubicin; C: Cyclophosphamide, cyclophosphamide); FEC: (F: Fluorouracil, fluorouracil; E: Epirubicin, EPI, epirubicin; C: Cyclophosphamide); TAC: (T: Docetaxel, docetaxel; A: Pirarubicin, THP, pirarubicin; C: Cyclophosphamide); AC: (A: Pirarubicin, THP, pirarubicin; C: Cyclophosphamide); EC: (E: Epirubicin, EPI, epirubicin; C: Cyclophosphamide); 3. ECG, myocardial enzyme, troponin and other cardiac indexes were normal before enrollment; 4. No other drugs that may affect ECG were used during chemotherapy treatment; 5. No history of cardiac surgery or other heart related problems; 6. The patient did not receive any other treatment before receiving chemotherapy; 7. One week before enrollment, the organ function reached the following standards: 1) Hemoglobin >= 100g/L; 2) White blood cell count >= 4.0 x 10^9/L or neutrophil count >= 2.0 x 10^9/L; 3) Platelet count >= 100 x 10^9/L; 4) Serum total bilirubin level <= 1.5 times the upper normal limit; 5) Aspartate transaminase AST <= 1.5 times the upper normal limit value; 6) Alanine transaminase ALT <= 1.5 times the upper limit of normal value; 7) Urea nitrogen <= 200mg/L; 8) Blood sugar: within normal range or controlled at normal level.
Exclusion criteria
Exclusion criteria: 1. Have a history of serious heart disease before chemotherapy, and have an acute attack within 3 months; 2. Imaging examination before chemotherapy showed pericardial effusion and coronary heart disease; 3. Biochemical examination showed that myocardial enzymes were elevated before chemotherapy, and cardiac function examination showed that EF < 60%; 4. Accompanied with a second primary cancer or distant metastasis; 5. The chemotherapy plan has not been completed or the medical records are incomplete due to various reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| electrocardiogram; | — |
Secondary
| Measure | Time frame |
|---|---|
| Echocardiography; | — |
Countries
China
Contacts
Public ContactLiang Tao
Chinese Academy of Medical Sciences / Peking Union Medical College
Outcome results
None listed